Sana Biotechnology (NASDAQ:SANA) Trading Up 6.8% – Here’s What Happened

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose 6.8% on Monday . The company traded as high as $3.47 and last traded at $3.3950. Approximately 529,515 shares traded hands during trading, a decline of 83% from the average daily volume of 3,177,092 shares. The stock had previously closed at $3.18.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Finally, Wedbush upped their target price on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Sana Biotechnology Trading Up 0.3%

The business’s fifty day moving average is $3.27 and its 200 day moving average is $3.55. The company has a market cap of $915.57 million, a P/E ratio of -3.54 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in Sana Biotechnology by 148.4% in the 1st quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock worth $8,487,000 after purchasing an additional 1,760,610 shares during the period. Royal Bank of Canada boosted its position in shares of Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after acquiring an additional 5,338 shares during the period. Cetera Investment Advisers grew its stake in Sana Biotechnology by 50.2% during the first quarter. Cetera Investment Advisers now owns 26,181 shares of the company’s stock valued at $75,000 after acquiring an additional 8,750 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Sana Biotechnology by 118.9% during the first quarter. Dimensional Fund Advisors LP now owns 291,268 shares of the company’s stock valued at $839,000 after acquiring an additional 158,190 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Sana Biotechnology by 2.0% during the 1st quarter. Swiss National Bank now owns 342,600 shares of the company’s stock worth $987,000 after acquiring an additional 6,800 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.